Medtronic Stent Patent Ruling Makes DES Vulnerable; Will Guidant Cut Deal?
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will appeal a Delaware federal court patent infringement ruling against its Driver and S7 coronary stents and challenge the validity of Guidant's Lau patent, the firm says
You may also be interested in...
Medtronic v. Boston Scientific: Appeals Court Affirms Taxus Non-Infringement
Boston Scientific's Taxus, Express and NIR stents do not infringe four Medtronic stent design patents, the U.S. Court of Appeals for the Federal Circuit affirms in a May 26 ruling
Medtronic v. Boston Scientific: Appeals Court Affirms Taxus Non-Infringement
Boston Scientific's Taxus, Express and NIR stents do not infringe four Medtronic stent design patents, the U.S. Court of Appeals for the Federal Circuit affirms in a May 26 ruling
Medtronic Gears For Stent Patent Infringement Showdowns With J&J, Guidant
Medtronic's Endeavor drug-eluting stent program and current coronary stent line-up are unaffected by a recent Johnson & Johnson patent infringement ruling against the company, Medtronic insists